News | eXCELL Biotherapeutic

We are thrilled to be participating in the 2025 Meet Taipei Startup Festival, showcasing how strategic Patent Innovation is accelerating the future of medicine!

At the heart of our exhibit is our groundbreaking xenogeneic cell cancer immunotherapy. We're leveraging the body's natural immune response to non-self cells to develop a powerful, constructive new treatment modality for difficult-to-treat cancers and other intractable diseases.

This proprietary platform, protected by our growing portfolio of global patents, demonstrates our commitment to transforming patient outcomes. We believe the future of cellular medicine is here—and it's driven by IP.

Join us at the NEXT IS NOW: Patent Driven, Global View special zone to explore how our innovations are moving from lab to clinic. Let's build a healthier world, together.

eXCELL Biotech is Paving the Way for Transformative Cancer Treatment at Meet Taipei 2025

由 eXCELL 發佈 | 2025-12-29

The Cell & Gene Meeting on the Mesa, 2025 in Phoenix, Arizona

The Cell & Gene Meeting on the Mesa, 2025 in Phoenix, Arizona

由 eXCELL 發佈 | 2025-12-29

2025 Biotechnology Industry Development Strategy Forum

益肸胞生醫2025 年入選資誠創業成長加速器第七屆新創輔導計畫

由 eXCELL 發佈 | 2025-08-26

Our Taiwan patent on intravesical xenogeneic urothelail cell immunotherapy for bladder cancer has been issued!

Our Taiwan patent on intravesical xenogeneic urothelail cell immunotherapy for bladder cancer has been issued!

由 eXCELL 發佈 | 2024-07-31

Taiwan Startup World Cup Entrepreneurship Competition

[eXCELL Biotherapeutics Inc was selected into the top 15 finalists of the 2024 Taiwan Startup World Cup]
After review by the U.S. organizer, eXCELL Biotherapeutics Inc. was selected as the finalist of the 2024 Taiwan Startup World Cup Entrepreneurship Competition

益肸胞生醫獲選2024 Taiwan Startup World Cup進入最終決賽

由 eXCELL 發佈 | 2024-07-18

Today, 2024, June 4, the Legislative Yuan passed the Regenerative Medicine Act and Regenerative Pharmaceuticals act with a third and final reading, ushering a new era of regenerative medicine. Xenogeneic cell therapy is included and regulated in both acts. As a leader and pioneer in xenogeneic cell cancer immunotherapy, eXCEL is dedicated to bringing our transformative cellular medicine to the clinics to ameliorate the lives of cancer patients.

The Regenerative Medicine Act and Regenerative Pharmaceuticals act Approval in Taiwan

由 eXCELL 發佈 | 2024-06-06

再生醫療法由朝野黨團、公私團體及行政部門歷經多年來的共同努力，於113年6月4日由立法院完成三讀。對於尚缺乏治療方法，或現有治療方式效果不佳之急重症病人，除了參與人體臨床試驗之外，先進國家莫不積極尋求解決之道，著重於應用醫療創新以增加拯救生命的機會。為呼應此一未被滿足的醫療需求，衛生福利部自107年起著手「再生醫療法」籌備工作，今終於完成立法，是確保醫療機構執行再生醫療之安全及品質、維護病人接受治療之權益的重大里程碑。

再生醫療法的通過，除促進再生醫療領域發展，亦加速再生醫療研發成果擴大應用至臨床醫學。全文共計35條七章節，重點如下：

一、研究發展促進：為確保提供病人安全有效之治療，醫療機構執行再生醫療前應進行並完成人體試驗，以促進再生醫療研究發展，予以獎勵或補助。

二、再生技術管理：明定醫療機構執行再生醫療之範疇、執行醫師之資格及應向病人充分說明相關權利義務等事項，以確保再生醫療之安全、品質及有效性。

三、細胞源頭管理：細胞操作執行機構及細胞保存庫，應對組織、細胞提供者進行合適性判定。

四、加重罰則：因再生醫療之執行影響病人生命、身體或健康甚鉅，除加重對非醫療機構執行再生醫療或為再生醫療廣告之處罰至最高2千萬元外，非醫療機構執行再生醫療，得沒入其執行再生醫療之設備及再生製劑。

衛生福利部再次感謝朝野立委及民間團體之協助與溝通，透過本次立法呼應再生醫療之臨床實務管理需求及產業發展需求，對確保再生醫療安全、品質及有效性，維護病人權益，至為關鍵。

立法院三讀通過「再生醫療法」開啟再生醫療新里程

由 eXCELL 發佈 | 2024-06-06

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,891,628 entitled, “Method for biomimetic culture of urothelial cells and uses thereof.” invented by co-founders Drs. Chih-Rong, Shyr and Chih-Ping Huang on February 6, 2024.
This patent owned by eXCELL Biotherapeutics INC. is a breakthrough xenogeneic cell-based therapy for treating bladder cancer by harnessing the body’s immune system.

The Japanese Patent has been published on 19 December. Patent No. 7272676 on May 1, 2023. Chinese Patent and Taiwan Patent are still pending. This patent family owned by eXCELL demonstrates the company's pioneering and leading role in xenogeneic cell cancer immunotherapy field.

2024 New Breakthrogh~ US patent on xenogeneic urothelial cell therapy on bladder cancer has been issued

由 eXCELL 發佈 | 2024-02-08

Immunotherapy, cell therapy

2023 eXCELL Biotech Received a Japan Patent for the method to manufacture xenogeneic urothelial cells and the theraputic use of intravesical administration of xenogeneic urothelial cells to treat bladder cancer and cystitis.

由 eXCELL 發佈 | 2023-07-08

2023 BIO International Convention

eXCELL Biotherapeutics Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities

由 eXCELL 發佈 | 2023-06-05

Immunotherapy

2022/01 再生醫療三法革命修正細胞定義跨到異種

由 eXCELL 發佈 | 2022-01-10

cell therapy

Oct.10. 2022 eXCELL, Inc., granted a pre-pre-Investigational IND for Regulatory Advice on CBER products INTERACT meeting with U.S. FDA

由 eXCELL 發佈 | 2022-10-10

white and red plastic tools

Nov.19. 2022 Announces Successful Completion of INTERACT, pre-IND Meeting with FDA

由 eXCELL 發佈 | 2022-11-19

he Small Business Innovation Research) grant (1)

Congratulation eXCELL on receiving SBIR 2023 Award

由 eXCELL 發佈 | 2023-02-19

Immunotherapy, cell therapy

March 2, 2023 NZeno, a New Zealand Company Agree to support eXCELL

由 eXCELL 發佈 | 2023-03-12

Immunotherapy, cell therapy

March 1, 2023 Meeting up PharmaSols, a New Zealand clinical research organisation that delivers exceptional clinical trials for medicine

由 eXCELL 發佈 | 2023-03-19

2023 BIO International Convention

eXCELL Biotherapeutics Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities

由 eXCELL 發佈 | 2023-06-05

Immunotherapy, cell therapy

2023 eXCELL Biotech Received a Japan Patent for the method to manufacture xenogeneic urothelial cells and the theraputic use of intravesical administration of xenogeneic urothelial cells to treat bladder cancer and cystitis.

由 eXCELL 發佈 | 2023-07-08

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,891,628 entitled, “Method for biomimetic culture of urothelial cells and uses thereof.” invented by co-founders Drs. Chih-Rong, Shyr and Chih-Ping Huang on February 6, 2024.
This patent owned by eXCELL Biotherapeutics INC. is a breakthrough xenogeneic cell-based therapy for treating bladder cancer by harnessing the body’s immune system.

The Japanese Patent has been published on 19 December. Patent No. 7272676 on May 1, 2023. Chinese Patent and Taiwan Patent are still pending. This patent family owned by eXCELL demonstrates the company's pioneering and leading role in xenogeneic cell cancer immunotherapy field.

2024 New Breakthrogh~ US patent on xenogeneic urothelial cell therapy on bladder cancer has been issued

由 eXCELL 發佈 | 2024-02-08

再生醫療法由朝野黨團、公私團體及行政部門歷經多年來的共同努力，於113年6月4日由立法院完成三讀。對於尚缺乏治療方法，或現有治療方式效果不佳之急重症病人，除了參與人體臨床試驗之外，先進國家莫不積極尋求解決之道，著重於應用醫療創新以增加拯救生命的機會。為呼應此一未被滿足的醫療需求，衛生福利部自107年起著手「再生醫療法」籌備工作，今終於完成立法，是確保醫療機構執行再生醫療之安全及品質、維護病人接受治療之權益的重大里程碑。

再生醫療法的通過，除促進再生醫療領域發展，亦加速再生醫療研發成果擴大應用至臨床醫學。全文共計35條七章節，重點如下：

一、研究發展促進：為確保提供病人安全有效之治療，醫療機構執行再生醫療前應進行並完成人體試驗，以促進再生醫療研究發展，予以獎勵或補助。

二、再生技術管理：明定醫療機構執行再生醫療之範疇、執行醫師之資格及應向病人充分說明相關權利義務等事項，以確保再生醫療之安全、品質及有效性。

三、細胞源頭管理：細胞操作執行機構及細胞保存庫，應對組織、細胞提供者進行合適性判定。

四、加重罰則：因再生醫療之執行影響病人生命、身體或健康甚鉅，除加重對非醫療機構執行再生醫療或為再生醫療廣告之處罰至最高2千萬元外，非醫療機構執行再生醫療，得沒入其執行再生醫療之設備及再生製劑。

衛生福利部再次感謝朝野立委及民間團體之協助與溝通，透過本次立法呼應再生醫療之臨床實務管理需求及產業發展需求，對確保再生醫療安全、品質及有效性，維護病人權益，至為關鍵。

立法院三讀通過「再生醫療法」開啟再生醫療新里程

由 eXCELL 發佈 | 2024-06-06

關閉

輸入您想搜尋的商品關鍵字，開始進行搜尋吧！

©2026 Copyrights eXCELL Biotherapeutics Inc. All Rights Reserved | 網站系統建置 By SGI